Auxogyn Appoints Women's Health Leader, Kathryn A. Tunstall, to Board of Directors

Auxogyn Appoints Women's Health Leader, Kathryn A. Tunstall, to Board of 
Directors 
MENLO PARK, CA -- (Marketwire) -- 02/28/13 --  Auxogyn, Inc., a
company focused on revolutionizing the field of reproductive health,
today announced the appointment of Kathryn A. Tunstall to the
company's Board of Directors. Ms. Tunstall is currently chairman of
the Board of Directors of Conceptus, Inc. (NASDAQ: CPTS), the leader
in the development of innovative device-based solutions in permanent
birth control.  
"Kathryn is a valuable addition to our board with her extensive
experience in the field of women's reproductive health and leadership
in growing early stage companies to successful enterprises. Kathryn
was the first CEO of Conceptus and under her leadership, the company
rapidly grew to be a worldwide leader in bringing innovative
solutions to the field of women's reproductive health," said Lissa
Goldenstein, president and chief executive officer of Auxogyn. "Her
experience will be instrumental in this next stage for Auxogyn, as we
continue to expand the commercialization of our flagship product, the
Eeva(TM) Test, which is currently available throughout the UK and
Ireland." 
Ms. Tunstall has served as chairman of the Board of Directors of
Conceptus, Inc., since January 2000 and as a member of the company's
Board of Directors since her appointment as CEO in July 1993. Prior
to joining Conceptus, she was employed by Edwards Less Invasive
Surgery Division of Baxter International, where she held a number of
positions including president. Earlier in her career, she held
various positions in finance, operations and marketing at American
Hospital Supply Corporation. Ms. Tunstall also served as a director
and compensation committee chair of Caliper LifeSciences, a
publicly-traded biotechnology company, until its acquisition by
Perkin Elmer, Inc. in November, 2011. She holds a B.A. in economics
from the University of California and has completed graduate-level
studies in business and healthcare administration. 
"With one in six couples experiencing infertility, there is a
tremendous need for technology to improve outcomes in order to help
couples achieve their dream of having a healthy child. I'm pleased to
be joining the Board of Directors at Auxogyn," said Kathryn Tunstall.
"The Eeva Test brings a technological breakthrough to in vitro
fertilization (IVF), offering objective information to clinical teams
to predict which embryos are the most viable and ultimately, to help
patients increase their odds for success."  
About the Eeva(TM) Test
 Auxogyn's non-invasive Early Embryo
Viability Assessment (Eeva) Test is designed to improve IVF outcomes
by providing clinicians and patients with objective information that
will enable them to more confidently select the best embryo(s) for
transfer. Eeva provides quantitative and objective information on the
early stages of the embryo's development and predicts the viability
of each embryo. Eeva's proprietary software automatically analyzes
embryo development against scientifically and clinically validated
cell-division parameters. With Eeva, IVF clinics may be able to
optimize the treatment path for their patients undergoing IVF
procedures. The Eeva Test is CE Mark approved and is available in
clinics throughout the United Kingdom and Ireland. In the United
States, the Eeva Test is pending 510K clearance and is limited to
investigational use only. For more information regarding Eeva, please
visit eevaivf.com or follow on Twitter @ EevaIVF.  
About Auxogyn
 Auxogyn is revolutionizing the field of reproductive
medicine by translating scientific discoveries in early embryo
development into clinical tools. The Company's flagship product, the
Eeva(TM) Test, delivers consistent, objective and quantitative
information regarding embryo viability that reproductive
endocrinologists and infertility patients can use to make important
treatment decisions. Auxogyn is privately held and funded by Kleiner
Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG
Biotech. For more information regarding Auxogyn, please visit
www.auxogyn.com or follow on Twitter @Auxogyn. 
Contact: 
Nicole Foderaro 
BrewLife 
(415) 946-1058 
nfoderaro@brewlife.com 
 
 
Press spacebar to pause and continue. Press esc to stop.